Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia

Table 1

Patient characteristics.

Characteristics
Median age, years (range)	46 (20–58)
Male gender, n (%)	16 (62%)
Median BMI (range)	28.2 (18.4–39.6)
AML diagnosis, n (%)
(i) De novo	23 (88%)
(ii) Treatment-related	3 (12%)
Prior MDS, n (%)	3 (12%)
ECOG performance status, median (range)	1 (0–2)
Disease status, n (%)
(i) Refractory	18 (69%)
(ii) Relapsed	8 (31%)
Prior therapies, median (range)	1 (1–4)
Prior treatments
7 + 3	23 (88%)
HiDAC	8 (31%)
Etoposide/mitoxantrone	2 (8%)
Prior allo-HCT, n (%)	2 (8%)
Genetic risk group [3], n (%)
Favorable	5 (19%)
Intermediate I	10 (39%)
Intermediate II	6 (23%)
Poor risk	5 (19%)

BMI: body mass index, AML: acute myeloid leukemia, MDS: myelodysplastic syndromes, ECOG: Eastern Cooperative Oncology Group, 7 + 3: cytarabine + anthracycline chemotherapy, HiDAC: high-dose cytarabine, and HCT: hematopoietic cell transplant.